These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32564750)

  • 41. Molecular Modeling Studies of Novel Fluoroquinolone Molecules.
    Allaka TR; Katari NK; Veeramreddy V; Anireddy JS
    Curr Drug Discov Technol; 2018; 15(2):109-122. PubMed ID: 28875852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigation of fluoroquinolone resistance mechanism in Mycoplasma hominis isolated from urogenital samples in a Chinese hospital.
    Zhang H; Zheng L; Zhao J; Ding S; Xia Y
    J Med Microbiol; 2019 Feb; 68(2):206-210. PubMed ID: 30632961
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant Neisseria gonorrhoeae Isolates.
    Hamasuna R; Ohnishi M; Matsumoto M; Okumura R; Unemo M; Matsumoto T
    Microb Drug Resist; 2018; 24(1):30-34. PubMed ID: 28581359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.
    Aldred KJ; Blower TR; Kerns RJ; Berger JM; Osheroff N
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E839-46. PubMed ID: 26792518
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Fluoroquinolones in ophthalmology: mechanisms of action and resistance].
    Labetoulle M; Chiquet C
    J Fr Ophtalmol; 2008 Oct; 31(8):795-801. PubMed ID: 19107047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The expanding role of fluoroquinolones.
    Schaeffer AJ
    Am J Med; 2002 Jul; 113 Suppl 1A():45S-54S. PubMed ID: 12113871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. History of quinolones and their side effects.
    Rubinstein E
    Chemotherapy; 2001; 47 Suppl 3():3-8; discussion 44-8. PubMed ID: 11549783
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A; Schubert S
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
    Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
    Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequent topoisomerase IV mutations associated with fluoroquinolone resistance in Ureaplasma species.
    Song J; Qiao Y; Kong Y; Ruan Z; Huang J; Song T; Zhang J; Xie X
    J Med Microbiol; 2015 Nov; 64(11):1315-1320. PubMed ID: 26243148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluoroquinolones as chemotherapeutics against mycobacterial infections.
    Jacobs MR
    Curr Pharm Des; 2004; 10(26):3213-20. PubMed ID: 15544510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
    Scoper SV
    Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
    Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
    Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Profile of a Novel Anionic Fluoroquinolone-Delafloxacin.
    Tulkens PM; Van Bambeke F; Zinner SH
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S213-S222. PubMed ID: 30957164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria.
    Skepper CK; Armstrong D; Balibar CJ; Bauer D; Bellamacina C; Benton BM; Bussiere D; De Pascale G; De Vicente J; Dean CR; Dhumale B; Fisher LM; Fuller J; Fulsunder M; Holder LM; Hu C; Kantariya B; Lapointe G; Leeds JA; Li X; Lu P; Lvov A; Ma S; Madhavan S; Malekar S; McKenney D; Mergo W; Metzger L; Moser HE; Mutnick D; Noeske J; Osborne C; Patel A; Patel D; Patel T; Prajapati K; Prosen KR; Reck F; Richie DL; Rico A; Sanderson MR; Satasia S; Sawyer WS; Selvarajah J; Shah N; Shanghavi K; Shu W; Thompson KV; Traebert M; Vala A; Vala L; Veselkov DA; Vo J; Wang M; Widya M; Williams SL; Xu Y; Yue Q; Zang R; Zhou B; Rivkin A
    J Med Chem; 2020 Jul; 63(14):7773-7816. PubMed ID: 32634310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of a Novel Fluoroquinolone Antibiotic Candidate WFQ-228 with Potent Antimicrobial Activity and the Potential to Overcome Major Drug Resistance.
    Hirano T; Kinoshita T; Kazamori D; Inoue S; Nishimura K; Sakurai A; Ohishi K; Kuramoto Y; Amano H; Yazaki A
    Chem Pharm Bull (Tokyo); 2018 Mar; 66(3):235-238. PubMed ID: 29321384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
    Hsueh PR; Chen WH; Luh KT
    Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular determinants of the bacterial resistance to fluoroquinolones: a computational study.
    Lupala CS; Gomez-Gutierrez P; Perez JJ
    Curr Comput Aided Drug Des; 2013 Jun; 9(2):281-8. PubMed ID: 23106777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.